A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 815 participants.

Also called NCT07218029

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 815 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07218029
  • EU CT 2025-521970-33-00
  • WHO UTN U1111-1321-4943
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Portugal, Serbia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07218029. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-12 (actual); primary completion 2028-12-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Acronym
SOTERIA
Condition
Pulmonary Arterial Hypertension
Intervention (Biological)
Sotatercept
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct07218029
Content hash
b8808948b48a224a012a9d836bedeaa4ca018e59d0b215f9045af9ecc8f55f41